

# J Genesca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2793063/publications.pdf>

Version: 2024-02-01

141  
papers

10,158  
citations

36303

51  
h-index

36028

97  
g-index

158  
all docs

158  
docs citations

158  
times ranked

7230  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. Journal of Virology, 1992, 66, 3225-3229.	3.4	858
2	HEPATITIS C VIRUS ANTIBODIES AMONG RISK GROUPS IN SPAIN. Lancet, The, 1989, 334, 294-297.	13.7	833
3	β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, The, 2019, 393, 1597-1608.	13.7	375
4	A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding. Gastroenterology, 2014, 146, 412-419.e3.	1.3	285
5	Cardiac alterations in cirrhosis: reversibility after liver transplantation. Journal of Hepatology, 2005, 42, 68-74.	3.7	281
6	High Prevalence of Hepatitis C Virus Infection in Diabetic Patients. Diabetes Care, 1996, 19, 998-1000.	8.6	253
7	High Rate of Infectivity and Liver Disease in Blood Donors with Antibodies to Hepatitis C Virus. Annals of Internal Medicine, 1991, 115, 443-449.	3.9	251
8	Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study. Hepatology, 2016, 64, 2173-2184.	7.3	251
9	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology, 2016, 150, 1160-1170.e3.	1.3	232
10	Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. Hepatology, 2017, 65, 1293-1305.	7.3	225
11	Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology, 2017, 66, 1980-1988.	7.3	223
12	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. Journal of Hepatology, 2020, 72, 688-701.	3.7	223
13	High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. Journal of Hepatology, 2020, 73, 705-708.	3.7	213
14	High Prevalence of Glucose Abnormalities in Patients With Hepatitis C Virus Infection: A multivariate analysis considering the liver injury. Diabetes Care, 2004, 27, 1171-1175.	8.6	183
15	Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver International, 2017, 37, 694-699.	3.9	178
16	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. Gastroenterology, 2018, 154, 1694-1705.e4.	1.3	162
17	Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: A double-blind RCT. Hepatology, 2003, 37, 1260-1266.	7.3	149
18	Preemptive TIPSS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. Hepatology, 2019, 69, 282-293.	7.3	144

#	ARTICLE	IF	CITATIONS
19	Development of hyperdynamic circulation and response to $\beta$ -blockers in compensated cirrhosis with portal hypertension. <i>Hepatology</i> , 2016, 63, 197-206.	7.3	143
20	Predicting Early Mortality After Acute Variceal Hemorrhage Based on Classification and Regression Tree Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1347-1354.	4.4	137
21	Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. <i>Journal of Hepatology</i> , 2020, 72, 472-480.	3.7	130
22	Detection of early portal hypertension with routine data and liver stiffness in patients with asymptomatic liver disease: A prospective study. <i>Journal of Hepatology</i> , 2014, 60, 561-569.	3.7	124
23	Sustained Virological Response Correlates With Reduction in the Incidence of Glucose Abnormalities in Patients With Chronic Hepatitis C Virus Infection. <i>Diabetes Care</i> , 2006, 29, 2462-2466.	8.6	118
24	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	3.7	112
25	Effectiveness of Combined Pharmacologic and Ligation Therapy in High-Risk Patients With Acute Esophageal Variceal Bleeding. <i>American Journal of Gastroenterology</i> , 2011, 106, 1787-1795.	0.4	108
26	Interferon- $\alpha$ in acute posttransfusion hepatitis C: A randomized, controlled trial. <i>Hepatology</i> , 1992, 15, 767-769.	7.3	107
27	Impact of anticoagulation on upper gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. <i>Hepatology</i> , 2015, 62, 575-583.	7.3	105
28	Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 723-732.	0.4	105
29	Interleukin-6, Nitric Oxide, and the Clinical and Hemodynamic Alterations of Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 1999, 94, 169-177.	0.4	103
30	Isosorbide Mononitrate in the Prevention of First Variceal Bleed in Patients Who Cannot Receive $\beta$ -blockers. <i>Gastroenterology</i> , 2001, 121, 908-914.	1.3	103
31	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1140-1150.	3.7	97
32	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2021, 160, 193-205.e10.	1.3	97
33	Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. <i>Hepatology</i> , 2020, 71, 658-669.	7.3	95
34	Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive $\beta$ -blockers. <i>Gastroenterology</i> , 2001, 121, 908-914.	1.3	94
35	Physiopathology of splanchnic vasodilation in portal hypertension. <i>World Journal of Hepatology</i> , 2010, 2, 208.	2.0	94
36	WHAT DO WESTERN BLOT INDETERMINATE PATTERNS FOR HUMAN IMMUNODEFICIENCY VIRUS MEAN IN EIA-NEGATIVE BLOOD DONORS?. <i>Lancet</i> , The, 1989, 334, 1023-1025.	13.7	85

#	ARTICLE	IF	CITATIONS
37	Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. <i>Hepatology</i> , 2018, 67, 1485-1498.	7.3	85
38	ROLE OF DOPPLER ECHOCARDIOGRAPHY IN THE ASSESSMENT OF PORTOPULMONARY HYPERTENSION IN LIVER TRANSPLANTATION CANDIDATES <sup>1</sup> . <i>Transplantation</i> , 2001, 71, 572-574.	1.0	84
39	Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. <i>Gastroenterology</i> , 2019, 157, 705-719.e18.	1.3	82
40	Proinflammatory Cytokines, Insulin Resistance, and Insulin Secretion in Chronic Hepatitis C patients: A case-control study. <i>Diabetes Care</i> , 2006, 29, 1096-1101.	8.6	81
41	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 313-327.e6.	4.4	74
42	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 328-349.	0.5	71
43	Blood-Borne Non-A, Non-B Hepatitis: Hepatitis C. <i>Seminars in Liver Disease</i> , 1991, 11, 147-164.	3.6	67
44	Increased tumour necrosis factor $\alpha$ production in mesenteric lymph nodes of cirrhotic patients with ascites. <i>Gut</i> , 2003, 52, 1054-1059.	12.1	67
45	Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 446-452.	0.4	65
46	Structure of replicating hepatitis C virus (HCV) quasispecies in the liver may not be reflected by analysis of circulating HCV virions. <i>Journal of Virology</i> , 1997, 71, 1732-1734.	3.4	64
47	Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. <i>Journal of Hepatology</i> , 2022, 77, 1014-1025.	3.7	64
48	Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*Z vs) Tj ETQq0.0 0 rgBT /Overlock	1.3	63
49	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	3.7	59
50	Glucose Abnormalities in Patients with Hepatitis C Virus Infection: Epidemiology and pathogenesis. <i>Diabetes Care</i> , 2006, 29, 1140-1149.	8.6	55
51	Hemodynamic response to guided therapy for prevention of variceal rebleeding: An uncontrolled pilot study. <i>Hepatology</i> , 2006, 44, 806-812.	7.3	54
52	Multicenter External Validation of Risk Stratification Criteria for Patients With Variceal Bleeding. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 132-139.e8.	4.4	54
53	Elastography methods for the non-invasive assessment of portal hypertension. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 155-164.	3.0	54
54	Diabetes Is the Main Factor Accounting for the High Ferritin Levels Detected in Chronic Hepatitis C Virus Infection. <i>Diabetes Care</i> , 2004, 27, 2669-2675.	8.6	53

#	ARTICLE	IF	CITATIONS
55	Acute esophageal variceal bleeding: Current strategies and new perspectives. World Journal of Hepatology, 2010, 2, 261.	2.0	51
56	Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: Effect of treatment with interferon. Translational Research, 2001, 137, 38-42.	2.3	48
57	Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology, 2013, 58, 2079-2088.	7.3	48
58	Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: relationship to nitric oxide. Digestive Diseases and Sciences, 1999, 44, 372-376.	2.3	47
59	Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. Therapeutic Advances in Gastroenterology, 2017, 10, 619-629.	3.2	45
60	Clinical Correlation and Genetic Polymorphism of the Human Immunodeficiency Virus Proviral DNA Obtained after Polymerase Chain Reaction Amplification. Journal of Infectious Diseases, 1990, 162, 1025-1030.	4.0	44
61	Validating the Baveno VI recommendations for screening varices. Journal of Hepatology, 2017, 66, 459-460.	3.7	43
62	Hepatitis D virus RNA in acute delta infection: Serological profile and correlation with other markers of hepatitis D virus infection. Hepatology, 1988, 8, 1125-1129.	7.3	42
63	Glucose Abnormalities Are an Independent Risk Factor for Nonresponse to Antiviral Treatment in Chronic Hepatitis C. American Journal of Gastroenterology, 2007, 102, 2189-2195.	0.4	40
64	Hepatitis b virus replication in acute hepatitis B, acute hepatitis B virus-hepatitis delta virus coinfection and acute hepatitis delta superinfection. Hepatology, 1987, 7, 569-572.	7.3	38
65	Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. Journal of Hepatology, 2021, 75, 589-599.	3.7	36
66	Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH. Scientific Reports, 2019, 9, 20183.	3.3	35
67	A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats. Scientific Reports, 2017, 7, 40461.	3.3	33
68	Immunoprophylaxis of perinatal transmission of the hepatitis B virus: Efficacy of hepatitis B immune globulin and hepatitis B vaccine in a low-prevalence area. Journal of Medical Virology, 1986, 18, 381-391.	5.0	30
69	Hepatitis C virus infection in renal transplant recipients: epidemiology, clinical impact, serological confirmation and viral replication. Journal of Hepatology, 1995, 22, 272-277.	3.7	30
70	Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding. Hepatology, 2012, 56, 706-714.	7.3	30
71	Spontaneous portosystemic shunts in liver cirrhosis: new approaches to an old problem. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482096128.	3.2	30
72	Role of immunosuppression in the development of quinolone-resistant Escherichia coli spontaneous bacterial peritonitis and in the mortality of E. coli spontaneous bacterial peritonitis. Alimentary Pharmacology and Therapeutics, 2003, 17, 695-701.	3.7	29

73	Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension. Journal of Hepatology, 2008, 49, 43-51.	3.7	28
74	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. Gut, 2022, 71, 415-423.	12.1	28
75	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. Journal of Hepatology, 2021, 75, 342-350.	3.7	28
76	Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients. Therapeutic Advances in Gastroenterology, 2016, 9, 823-835.	3.2	25
77	Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study. BMJ Open Diabetes Research and Care, 2019, 7, e000845.	2.8	24
78	Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: Final report of a prospective trial. Hepatology, 1995, 22, 439-445.	7.3	23
79	Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension. Liver International, 2010, 30, 593-602.	3.9	23
80	High doses of Î²-blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding. Liver International, 2010, 30, 1123-1130.	3.9	23
81	Enfermedades vasculares del h�gado. Gu�as Cl�nicas de la Sociedad Catalana de Digestolog�a y de la Asociaci�n Espa�ola para el Estudio del H�gado. Gastroenterolog�a Y Hepatolog�a, 2017, 40, 538-580.	0.5	20
82	Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFAH). Liver International, 2022, 42, 1109-1120.	3.9	20
83	Validation of Automated Blood Cell Counters for the Diagnosis of Spontaneous Bacterial Peritonitis. American Journal of Gastroenterology, 2004, 99, 1400-1400.	0.4	19
84	Role of host and bacterial virulence factors in Escherichia coli spontaneous bacterial peritonitis. European Journal of Gastroenterology and Hepatology, 2008, 20, 924-929.	1.6	19
85	Cerebellar neurodegeneration in a new rat model of episodic hepatic encephalopathy. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 927-937.	4.3	18
86	Clinical and serological outcome of acute delta infection. Journal of Hepatology, 1987, 5, 59-64.	3.7	17
87	Hepatitis C virus markers in patients with acute post-transfusion hepatitis treated with interferon alfa-2b.. Gut, 1993, 34, S62-S63.	12.1	16
88	Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: Final report of a prospective trial*1. Hepatology, 1995, 22, 439-445.	7.3	16
89	Predicting 6-week mortality after acute variceal bleeding: role of classification and regression tree analysis. Annals of Hepatology, 2009, 8, 308-315.	1.5	15
90	Basal values and changes of liver stiffness predict the risk of disease progression in compensated advanced chronic liver disease. Digestive and Liver Disease, 2016, 48, 1214-1219.	0.9	15

#	ARTICLE	IF	CITATIONS
91	Blockage of the afferent sensitive pathway prevents sympathetic atrophy and hemodynamic alterations in rat portal hypertension. Liver International, 2012, 32, 1295-1305.	3.9	14
92	Hepatitis C: molecular biology, pathogenesis, epidemiology, clinical features, and prevention. Progress in Liver Diseases, 1992, 10, 253-82.	0.3	14
93	Simvastatin-loaded polymeric micelles are more effective and less toxic than conventional statins in a pre-clinical model of advanced chronic liver disease. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 29, 102267.	3.3	12
94	Enfermedad hepática por alcohol. Guías de práctica clínica. Documento de consenso auspiciado por la AEEH. Gastroenterología Y Hepatología, 2019, 42, 657-676.	0.5	12
95	Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats. Hepatology, 2012, 56, 1849-1860.	7.3	11
96	Alcohol consumption and risk of infection after a variceal bleeding in low-risk patients. Liver International, 2016, 36, 994-1001.	3.9	11
97	Identifying Compensated Advanced Chronic Liver Disease: When (Not) to Start Screening for Varices and Clinically Significant Portal Hypertension. , 2016, , 39-49.		11
98	High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. Clinical Microbiology and Infection, 2017, 23, 775.e1-775.e6.	6.0	11
99	Covert hepatic encephalopathy and spontaneous portosystemic shunts increase the risk of developing overt hepatic encephalopathy. Liver International, 2020, 40, 3093-3102.	3.9	11
100	Nitric oxide may contribute to nocturnal hemodynamic changes in cirrhotic patients. American Journal of Gastroenterology, 2000, 95, 1539-1544.	0.4	10
101	Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. Gastroenterología Y Hepatología (English Edition), 2017, 40, 538-580.	0.1	10
102	Utility of Transient Elastography for the Screening of Liver Disease in Patients with Alpha1-Antitrypsin Deficiency. Journal of Clinical Medicine, 2021, 10, 1724.	2.4	10
103	Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. Therapeutic Advances in Gastroenterology, 2018, 11, 1756283X1774341.	3.2	9
104	Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH. DMM Disease Models and Mechanisms, 2021, 14, .	2.4	9
105	Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role?. European Journal of Gastroenterology and Hepatology, 2002, 14, 81-83.	1.6	8
106	Inhibition of Neuronal Apoptosis and Axonal Regression Ameliorates Sympathetic Atrophy and Hemodynamic Alterations in Portal Hypertensive Rats. PLoS ONE, 2014, 9, e84374.	2.5	8
107	WHEN SHOULD AT-RISK INFANTS BE BOOSTED WITH HEPATITIS B VACCINE?. Lancet, The, 1987, 329, 49.	13.7	7
108	The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110165.	3.2	7



#	ARTICLE	IF	CITATIONS
109	Vascular endothelial growth factor levels in liver cirrhosis. Digestive Diseases and Sciences, 1999, 44, 1261-1262.	2.3	6
110	Adding banding ligation is effective as rescue therapy to prevent variceal rebleeding in haemodynamic non-responders to pharmacological therapy. Digestive and Liver Disease, 2012, 44, 55-60.	0.9	6
111	Should prophylactic embolization of spontaneous portosystemic shunts be routinely performed during transjugular intrahepatic portosystemic shunt placement?. Digestive and Liver Disease, 2018, 50, 1324-1326.	0.9	6
112	Reply to: "Definition of SPSS: we need to speak the same language". Journal of Hepatology, 2020, 73, 464-465.	3.7	6
113	Evaluation of anti-HCV positive blood donors identified during routine screening. Archives of Virology Supplementum, 1992, 4, 244-246.	3.0	6
114	Reply to "Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno VI consensus". Journal of Hepatology, 2015, 63, 1049-1050.	3.7	5
115	The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats. Liver International, 2015, 35, 326-334.	3.9	5
116	Diagnostic and Prognostic Markers in Liver Cirrhosis. Disease Markers, 2011, 31, 119-120.	1.3	5
117	Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 4885.	2.4	5
118	Disappearance of serum hepatitis B virus DNA by polymerase chain reaction after adenine arabinoside 5'-monophosphate therapy in chronic hepatitis B. Liver, 1993, 13, 136-140.	0.1	4
119	$\beta_1$ and $\beta_2$ -adrenergic agonists on cirrhotic patients with refractory ascites. Liver International, 2016, 36, 177-180.	3.9	4
120	Trends in Diagnosis of Alpha-1 Antitrypsin Deficiency Between 2015 and 2019 in a Reference Laboratory. International Journal of COPD, 2020, Volume 15, 2421-2431.	2.3	4
121	A Diet Combining High Fat and Glucose-Fructose Syrup Induces Obesity, Non-Alcoholic Steatohepatitis and Portal Hypertension in a New Animal Model. Journal of Hepatology, 2016, 64, S452-S453.	3.7	3
122	Ruling in and ruling out with elastography in compensated advanced chronic liver disease. Gut, 2017, 66, 197-198.	12.1	3
123	Beyond Baveno VI: How far are we?. Digestive and Liver Disease, 2019, 51, 1141-1143.	0.9	3
124	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. JHEP Reports, 2021, 3, 100368.	4.9	3
125	Comparison of four different antigen-capture assays for the detection of human immunodeficiency virus antigen (HIV-Ag). Journal of Acquired Immune Deficiency Syndromes, 1989, 2, 170-77.	1.0	3
126	Prognostic Evaluation of Patients with Acute Variceal Bleeding. Disease Markers, 2011, 31, 155-164.	1.3	2



#	ARTICLE	IF	CITATIONS
127	Steatosis as main determinant of portal hypertension through a restriction of hepatic sinusoidal area in a dietary rat nash model. Liver International, 2020, 40, 2732-2743.	3.9	2
128	Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?. Journal of Hepatology, 2021, 75, 750-752.	3.7	2
129	A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo. Biomedicines, 2022, 10, 1191.	3.2	2
130	Familial amyloidosis in a large Spanish kindred resulting from a D38V mutation in the transthyretin gene. European Journal of Clinical Investigation, 2007, 37, 673-678.	3.4	1
131	Evaluation and treatment of the critically ill cirrhotic patient. Gastroenterology Y Hepatology (English Edition), 2016, 39, 607-626.	0.1	1
132	Risk Stratification in Acute Variceal Bleeding: Child-Pugh Versus Model for End-stage Liver Disease. Journal of Clinical Gastroenterology, 2019, 53, 549-549.	2.2	1
133	Lack of HIV transmission after hepatitis B immunoprophylaxis. Infection, 1987, 15, 366-366.	4.7	0
134	Diabetes Is the Main Factor Accounting for the High Ferritin Levels Detected in Chronic Hepatitis C Virus Infection: Response to Sebastiani et al.. Diabetes Care, 2005, 28, 1838-1839.	8.6	0
135	Response to Heish et al.. American Journal of Gastroenterology, 2008, 103, 488-488.	0.4	0
136	Reply. Hepatology, 2014, 60, 1795-1796.	7.3	0
137	Risk Stratification with Noninvasive Tools in Patients with Compensated Cirrhosis. Current Hepatology Reports, 2017, 16, 228-236.	0.9	0
138	Reply. Gastroenterology, 2018, 155, 1650-1651.	1.3	0
139	Reply to: "Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma". Journal of Hepatology, 2020, 73, 1289-1290.	3.7	0
140	Reply to: "Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?" and "External validation of noninvasive predictors of hepatocellular carcinoma in patients with HCV advanced chronic liver disease after oral antivirals". Journal of Hepatology, 2020, 73, 472-473.	3.7	0
141	Prediction of hepatocellular carcinoma after sustained virologic response in patients with compensated advanced chronic liver disease. , 2021, 59, ,		0